Drug metabolism in Sprague-Dawley rat assessed as N-[6-(3-Hydroxypropyl)-5,11-dioxo-6,11-dihydro-5Hindeno[1,2-c]isoquinolin-3-yl]acetamide level in mammary gland at 40 mg/kg, po administered 3 days
Drug metabolism in Sprague-Dawley rat assessed as N-[6-(3-Hydroxypropyl)-5,11-dioxo-6,11-dihydro-5Hindeno[1,2-c]isoquinolin-3-yl]acetamide level in serum at 40 mg/kg, po administered 3 days
Drug metabolism in Sprague-Dawley rat assessed as N-[6-(3-Hydroxypropyl)-5,11-dioxo-6,11-dihydro-5Hindeno[1,2-c]isoquinolin-3-yl]acetamide level in liver at 40 mg/kg, po administered 3 days
Drug metabolism in Sprague-Dawley rat assessed as 3-Amino-11-hydroxy-6-(3-hydroxypropyl)-6,11-dihydro-5Hindeno[1,2-c]isoquinolin-5-one level in mammary gland at 40 mg/kg, po administered 3 days
Drug metabolism in Sprague-Dawley rat assessed as 3-Amino-11-hydroxy-6-(3-hydroxypropyl)-6,11-dihydro-5Hindeno[1,2-c]isoquinolin-5-one level in serum at 40 mg/kg, po administered 3 days
Drug metabolism in Sprague-Dawley rat assessed as 3-Amino-11-hydroxy-6-(3-hydroxypropyl)-6,11-dihydro-5Hindeno[1,2-c]isoquinolin-5-one level in liver at 40 mg/kg, po administered 3 days
Drug metabolism in Sprague-Dawley rat assessed as 6-(3-Hydroxypropyl)-3-amino-5H-indeno[1,2- c]-isoquinoline-5,11(6H)dione level in mammary gland at 40 mg/kg, po administered 3 days
Drug metabolism in Sprague-Dawley rat assessed as 6-(3-Hydroxypropyl)-3-amino-5H-indeno[1,2- c]-isoquinoline-5,11(6H)dione level in serum at 40 mg/kg, po administered 3 days
Drug metabolism in Sprague-Dawley rat assessed as 6-(3-Hydroxypropyl)-3-amino-5H-indeno[1,2- c]-isoquinoline-5,11(6H)dione level in liver at 40 mg/kg, po administered 3 days
Drug metabolism in Sprague-Dawley rat assessed as 3-Amino-6-(3-aminopropyl)-11-hydroxy-6,11-dihydro-5Hindeno[1,2-c]isoquinolin-5-one level in mammary gland at 40 mg/kg, po administered 3 days
Drug metabolism in Sprague-Dawley rat assessed as 3-Amino-6-(3-aminopropyl)-11-hydroxy-6,11-dihydro-5Hindeno[1,2-c]isoquinolin-5-one level in serum at 40 mg/kg, po administered 3 days
Drug metabolism in Sprague-Dawley rat assessed as 3-Amino-6-(3-aminopropyl)-11-hydroxy-6,11-dihydro-5Hindeno[1,2-c]isoquinolin-5-one level in liver at 40 mg/kg, po administered 3 days
Inhibition of TNFalpha-induced human NFkappaB activity in HEK293 cells incubated for 6 hrs followed by compound wash out measured after 5 mins by by luciferase assay
Inhibition of TNFalpha-induced human NFkappaB activity in HEK293 cells at 50 uM incubated for 6 hrs followed by compound wash out measured after 5 mins by by luciferase assay
Agonist activity at human RXRalpha expressed in african green monkey COS1 cells assessed as induction of RXRE transcriptional activity at 1.25 to 20 uM after 25 hrs by luciferase reporter gene assay relative to bexarotene
Agonist activity at human RXRalpha expressed in african green monkey COS1 cells assessed as induction of RXRE transcriptional activity at 1.25 to 20 uM after 4 to 6 hrs by luciferase reporter gene assay relative to control
Agonist activity at human RXRalpha expressed in african green monkey COS1 cells assessed as induction of RXRE transcriptional activity at 5 uM after 24 hrs by luciferase reporter gene assay relative to control
Agonist activity at human RXRalpha expressed in african green monkey COS1 cells assessed as induction of RXRE transcriptional activity after 12 hrs by luciferase reporter gene assay
Agonist activity at human RXRalpha expressed in african green monkey COS1 cells assessed as induction of RXRE transcriptional activity at 1.25 to 20 uM after 25 hrs by luciferase reporter gene assay relative to control